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CLINICAL STUDY
Pretransplant uric acid levels may be predictive for prognosis of renal
transplant donors
Eyup Kulah
Department of Nephrology, Baskent University School of Medicine, Istanbul, Turkey
ABSTRACT
Background The living kidney donor counseling prior to the operation may be helpful to learn
how to properly care for the remaining single kidney for the rest of their lives. Worsening kidney
function is associated with elevated serum uric acid (UA) levels. In this study, we compared the
baseline laboratory findings of renal transplant donors with their follow-up laboratory values.
Methods The study consisted of 173 adult donors including 91 females and 82 males with a mean
age of 46.82 ± 11.31 years. The follow-up clinical and laboratory examinations were performed on
the third day at the end of the first and the sixth months of the surgery. According to donor’s
creatinine levels we constituted two groups: high creatinine and normal creatinine. Results
Patients within the high creatinine group had significantly higher mean serum UA levels when
compared with the normal creatinine group. In multivariate analysis, among the other effective
variables, UA level alone was found to be the most effective parameter predicting the post-
transplant creatinine levels (p¼ 0.004, odds ratio: 12.4, 95% CI: 2.3–68.3) at sixth month post-
transplantation. In the ROC analysis for the effects of UA, the following cutoff values were found:
46mg/dL in men (sensitivity 81.3%, specificity 76.9%, positive predictive value 89.7%, negative
predictive value 62.5%, accuracy 80%) and 5mg/dL in women (sensitivity 72.2, specificity 74.4%,
positive predictive value 89.7%, negative predictive value 62.5%, accuracy: 73.7%). Conclusion
Pretransplant serum UA levels can give important clues regarding the renal functions of the donors
during the postoperative period.
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Introduction
Due to the reduction in the deceased donor pool, living
kidney donor use increases gradually during the recent
years.1 However, the living kidney donor pool fails to
cover the requirement due to various reasons. This
shortage in the living kidney donor pool mandates that
the donor selection criteria be pushed to its limits.2 For
example, people approaching the upper age limit or
lower glomerular filtration limit as well as overweight
persons are sometimes selected for the donation
process. Also, mildly hypertensive or glucose intolerant
donors are considered to be fit. Applying the living
kidney donor selection criteria within limits helps to
minimize the risk for complications.3 The risks and
benefits both for the donor and recipient should be
rigorously evaluated, and the risks should not exceed
the benefits for either of them.4 The follow-up controls
of the donors after the transplantation procedure are
not as frequent as it is for the recipients. Although
donors are evaluated prior to the donation, they may be
prone to renal insufficiency, hypertension, cardiovascular
diseases, or diabetes postoperatively. Donors lose
roughly 50% of their nephrons following the donation
procedure. In studies on donors, increased creatinine
values begin to subside at the end of the first week at
the earliest, and in some cases it may take several
months to reach normal values.5 Donor counseling prior
to the operation may be helpful to learn how to properly
care for the remaining single kidney for the rest of
their lives.
Uric acid (UA) is a product of purine metabolism and
is filtered through glomeruli and then reabsorbed from
the proximal tubules. This results in 70% excretion from
the kidneys and the remaining 30% is excreted through
the gastrointestinal tract.6 Worsening kidney function is
associated with elevated serum UA levels due to the
impairment of UA transport through nephrons.7
Elevated UA levels may also be a sign for the deterior-
ation of glomerular filtration rate (GFR) and the emer-
gence of a kidney disease.8 Renal parenchymal lesions
may be related with higher levels of UA.9 UA may be
associated with kidney damage through direct or
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indirect pathways. Endothelial dysfunction and elevated
renin–angiotensin–aldosterone activity associated with
higher UA levels may be directly related with the kidney
damage found in hyperuricemia.10
Hyperuricemia is also thought to be related with
kidney impairment through indirect pathways.
Microalbuminuria in Type II diabetes, untreated hyper-
tension, and pre-hypertension are presumed to be
related with serum UA levels.11,12 Renal functional
impairment in non-proteinuric Type I diabetics is
thought to be related with high-normal serum UA
levels.13 As a result, serum UA levels may be a predictor
for renal dysfunction. The predictor value of serum UA
levels in renal transplant donors is uncertain. In this
study, we compared the baseline laboratory findings of
renal transplant donors with their follow-up laboratory
values.
Methods
This study included living renal transplantation donors
during the years 2011–2015 in Baskent University’s two
different centers for renal transplantation. The study
consisted of 173 adult donors including 91 females and
82 males with a mean age of 46.82 ± 11.31 years. Donor
characteristics such as age, gender, past medical history,
use of any medications, physical examination findings,
and follow-up information were retrieved from the
medical database of the healthcare centers. All of the
subjects have undergone cardiological, respiratory,
gastroenterological, dental, and psychiatric consult-
ations. Blood urea nitrogen (BUN), creatinine, electro-
lytes, calcium (Ca), phosphorus (P), UA, high-sensitive
C-reactive protein (hs-CRP) levels were determined by
either the C8000 system (Abbott, USA) or Cobas e-411
(Roche, Germany) autoanalyzer. Urinary protein and
microalbumin levels were determined, and creatinine
clearance rates were calculated in all donors on a 24-h
urinary specimen prior to the donation surgery. The
follow-up clinical and laboratory examinations were
performed on the third day at the end of the first and
the sixth months of the surgery. The exclusion criteria for
the donors consisted of the following: age518 years,
body mass index (BMI)435, any use of medications for
hypertension or diabetes, presence of any kidney
disease, malignant or ongoing infectious diseases, car-
diovascular diseases, gout, any psychiatric disorders, or
elevated UA levels.
This study was conducted according to the Helsinki
declaration and the study protocol was approved by
the local institute’s Committee on Human Research
(our local ethics body). All of the subjects gave their
informed consents.
Statistical analysis
Statistical analyses were carried out using SPSS (SPSS Inc.
Version13.0, Chicago, IL, USA). The results were pre-
sented as means ± standard deviation for continuous
variables and frequency and percent values for categor-
ical variables. Mean values among groups were com-
pared by either Student’s T test when the distribution
was normal or Mann–Whitney U test if otherwise. A
logistic regression was used to identify the independent
predictors of the sixth month increase in creatinine.
Inclusion of variables was assessed using a forward
method. The receiver operating characteristic (ROC)
curve and the area under ROC (AUROC) curve analyses
were used to assess the utility of parameters in the levels
of UA. p-Values less than 0.05 were considered statistic-
ally significant.
Results
The demographic and laboratory values for the subjects
are depicted in Table 1. An increase of 30% or more in
creatinine values in any subject or a creatinine value of
41.4 in males and41.3 in females were considered to be
elevated at the end of the sixth month after surgery.
These criteria classified 71.1% of male and 32.1% of
female donors and an overall 49.5% of all of the donors
to be in the high creatinine group. The characteristics for
donors either with high or normal creatinine groups are
presented in Table 2. Patients within the high creatinine
group were predominantly male, had significantly higher
levels of pretransplant BUN, creatinine clearance rate,
and mean serum UA levels when compared with the
normal creatinine group. In multivariate analysis, among
the other effective variables such as age, pretransplant
creatinine, BUN, creatinine clearance rate of the living
Table 1. The demographic and laboratory values for the donors.
N 173
Male/female 82/91
Age (years) 46.82 ± 11.31
BMI (kg/m2) 28.56 ± 4.8
BUN (mg/dL) 12.78 ± 2.72
Creatinine clearance (mL/s) 132.85 ± 25.66
Sodium (mmol/L) 138.26 ± 2.22
Potassium (mmol/L) 4.17 ± 0.29
Calcium (mg/dL) 9.33 ± 0.62
Phosphorus (mg/dL) 3.71 ± 0.65
Magnesium (mg/dL) 2.10 ± 0.28
Uric acid (mg/dL) 5.24 ± 1.25
Third day creatinine (mg/dL) 1.12 ± 0.26
First month creatinine (mg/dL) 1.10 ± 0.24
Sixth month creatinine (mg/dL) 1.10 ± 0.25
hs-CRP (mg/L) 4.56 ± 4.16
24-h proteinuria (mg/24-h) 218.28 ± 85.60
24-h microalbuminuria (mg/24-h) 21.42 ± 24.69
Notes: BMI: body mass index, BUN: blood urea nitrogen, hs-CRP: high-
sensitive C-reactive protein; Age, BMI and all laboratory values:
(mean ± SD).
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donor, UA level alone was found to be the most effective
parameter predicting the post-transplant creatinine
levels (p¼ 0.004, odds ratio: 12.4, 95% CI: 2.3–68.3) at
sixth month post-transplantation.
In the ROC analysis for the effects of UA, the
following cutoff values were found:46mg/dL in men
(Figure 1) (sensitivity 81.3%, specificity 76.9%, positive
predictive value 89.7%, negative predictive value 62.5%,
accuracy 80%) and 5mg/dL in women (Figure 2)
(sensitivity 72.2, specificity 74.4%, positive predictive
value 89.7%, negative predictive value 62.5%,
accuracy: 73.7%).
Discussion
According to our renal function impairment criteria,
donors having UA levels higher than 6mg/dL in males
and 5mg/dL in females prior to surgery pose a signifi-
cantly higher risk for postoperative kidney function
impairment. In donors whose creatinine values still
persist at high levels at the end of the sixth month
may develop chronic kidney disease (CKD) sometime
later. We have not encountered any studies that
investigate the predictive value of the pretransplant
UA levels on the post-transplant kidney function in living
donors. The studies that evaluate the predictive value of
UA levels on renal function impairment mostly investi-
gate the values of the recipients. As there are a couple of
confounding factors that affect the UA levels in these
studies such as cyclosporine-induced hyperuricemia,
they are of limited value. In a study performed on
kidney transplantation recipients by Haririan et al.,
higher serum UA levels were found to be associated
with higher risk for graft loss and a decrease in estimated
GFR.14 However, Akalin et al. reported that death, graft
failure, new cardiovascular events, and chronic graft
nephropathy were more frequent in hyperuricemic
recipients.15 Bandukwala et al. demonstrated the asso-
ciation of hyperuricemia with the decrease in renal
allograft function in their study of 405 stable renal
transplant recipients.16 Renal graft outcomes were found
to be poorer in hyperuricemic recipients in general.
Studies on the relationship between UA levels
and renal function report equivocal results. In studies
performed on healthy individuals, UA levels were found
Figure 1. The ROC analysis for the effects of UA, cutoff values
46 mg/dL in men.
Figure 2. The ROC analysis for the effects of UA, cutoff values
5 mg/dL in women.
Table 2. The characteristics for donors either with high or
normal creatinine groups.
Normal creatinine
sixth month
group
High creatinine
sixth month
group p values
n 51 50
Age (years) 46.84 ± 11.28 49.48 ± 10.06 ns
Female/Male 38/13 18/32 50.0001
BUN (mg/dL) 12.29 ± 2.72 13.85 ± 2.51 0.041
BMI (kg/m2) 28.7 ± 4.8 27.55 ± 3.35 ns
Creatinine clearance (mL/s) 125.52 ± 25.04 145.05 ± 23.49 0.004
Sodium (mmol/L) 138.32 ± 2.04 138.20 ± 2.64 ns
Potassium (mmol/L) 4.15 ± 0.33 4.22 ± 0.24 ns
Calcium (mg/dL) 9.23 ± 0.72 9.54 ± 0.28 ns
Phosphorus (mg/dL) 3.80 ± 0.64 3.48 ± 0.65 ns
Uric acid (mg/dL) 4.46 ± 1.02 6.52 ± 0.70 50.0001
hs-CRP (mg/L) 4.11 ± 4.08 5.64 ± 4.36 ns
24-h proteinuria (mg/24-h) 208.82 ± 88.95 237.55 ± 81.81 ns
24-h microalbuminuria
(mg/24-h)
16.61 ± 8.60 30.68 ± 39.01 ns
Notes: ns: non-significant, BUN: blood urea nitrogen, hs-CRP: high-sensitive
C-reactive protein; Age, BMI and all laboratory values: (mean ± SD).
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to be a useful predictor during the follow-up of renal
functions. Increased UA levels were found to be
predictive for incipient kidney disease and end-stage
renal disease in people with normal renal function as
well as the progression in individuals with kidney
disease.17,18 While Ishani et al., in their study on male
subjects, report a relation between UA levels19 and end
stage kidney disease, an independent association was
only observed for women in another study from Japan.20
Zhang et al. studied a community-based Chinese popu-
lation with eGFR 460mL/min/1.73m2 and found UA
levels to be independently associated with the likelihood
for the decline in renal function.21 Although, the
association was not significant in the modification of
diet in renal disease (MDRD) study of Madero et al.22
Previous studies revealed inconsistent results, and
researches among the non-hypertensive and non-dia-
betic population are limited. As research regarding the
predictiveness of UA levels and kidney damage on the
non-hypertensive and non-diabetic population is scarce
in the literature, the present study has a value in itself.
The present study underlines that UA levels which may
be of importance during the living donor exclusion
process. As the donor loses almost 50% of its nephrons
instantly following the surgery, the benefits of donation
must outweigh the risks associated with the procedure.
The search regarding the risk factors and the clinical
course regarding the development of kidney dysfunc-
tion following kidney donation is still far from being
complete.23 Living donor assessment prior to kidney
donation aims at choosing the most suitable donor with
a minimum risk of complication.24 Because we are
currently pushing the donor selection criteria to its limits
(e.g., accepting donors with a GFR at lower limits,
overweight donors, donors with glucose intolerance,
elderly donors, and mildly hypertensive individuals on
monotherapy) to overcome the shortage of the living
donor pool, we presume that pretransplant UA values
may be useful for the follow-up of the donors after
surgical intervention. The literature discusses whether
the increase in UA is a result or a reason for kidney
function impairment. Not all of the hypertensive or
diabetic individuals universally have elevated levels of
UA. For instance, in the adult population, the prevalence
of prehypertension and hypertension is approximately
60%, whereas prevalence of hyperuricemia (defined as
UA46.0mg/dL in women and UA47.0mg/dL in men) is
approximately 17%.25 In such populations, UA may have
an enhancing role for end-organ impairment through
direct or indirect pathways. The nephrotoxic effect of
elevated UA levels is supported in animal experiments
and cellular biological studies. Higher UA levels leading
to glomerular hypertension, elevated renal vascular
resistance, reduced renal blood flow, activation of
renin–angiotensin system (RAS), arteriolosclerosis, glom-
erular hypertrophy, glomerulosclerosis, and interstitial
disease have been shown in various animal experiments.
In these studies, the mentioned effects were suggested
to be induced through oxidative stress and endothelial
dysfunction caused by higher levels of UA.26,27 Nitric
oxide generated in vitro in endothelial cells was found to
be directly impaired by UA.10 Our findings of UA levels
within normal range (57.2mg/dL in males and56mg/dL
in females) in the present study are of significance. In the
cardiovascular health study (CHS) of Choncol et al., a
strong correlation was observed between the baseline
kidney function and UA levels.28 Interestingly, although
the presence of a strong cross-sectional association
between baseline UA levels and baseline kidney function
was found along with an annual decrease of 3mL/min
1.73m2 in the patients 65 year of age with UA levels
45.9mg/dL in the longitudinal analysis, Choncol et al.
failed to disclose any significant relationship between
UA levels and incident CKD defined by eGFR560mL/min
per 1.73m2 in the final examination of their study results.
In non-proteinuric Type I diabetic patients with normal
to high levels of UA, an early decline in GFRs was
reported.13 Among these studies, Ficociello et al.
reported a 40% increase in the odds of developing
early GFR loss for every 1mg/dL increase in serum UA
level.29 The presence of a relation between the UA levels
and the baseline kidney function was suggested in other
studies.17 In a study by Gerhardt et al. including 350
kidney transplant recipients with functioning grafts one
year after the procedure, UA levels greater than
8.1mg/dL in men and 6.1mg/dL in women were found
to be associated with worsening graft survival in the
following five years when compared with normourice-
mic graft recipients (five-year rate 68.8% vs. 83.3%,
respectively).30 Studies on individuals with higher levels
of UA show that these people are more prone to obesity,
hypertension, diabetes, and cardiovascular events when
compared with normouricemic individuals.31 These dis-
eases and entities are among the factors that may affect
the renal function of the living donors either directly or
indirectly later on during their lives. These diseases are
significant risk factors for living donors following neph-
ron loss. In living donors with elevated UA levels,
precautions about the mentioned diseases and entities
may provide significant health benefits during their lives
following nephron loss. There are studies that report the
beneficial effects of UA-lowering dietary precautions and
medications in the progress of CKD. Sturm et al. followed
177 non-diabetic CKD patients (stage I–V) for seven years
looking for an association between UA levels and CKD
progression and observed that UA was not predictive for
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CKD progression. However, when they have excluded
the patients using UA-lowering drugs, the analyses
revealed a faster progression of CKD with high levels of
UA.32 Mild or moderate renal dysfunction is present in
20–60% of patients with gout.33 Before the availability of
UA lowering agents, as many as 10–25% of patients with
gout developed end-stage renal disease.34 In living
kidney donors, UA levels that approach their upper limits
but are within the normal range seem to be useful to
predict the postoperative elevation in the creatinine
levels in the present study. This observation leads us to
recommend UA-lowering drugs and precautions to be
effective in living donors, in whom UA levels approach
their upper limits but are within their normal range prior
to the operation. This may lessen the load and hence
preserve the function of the remaining kidney in the
living donors following the transplantation.
Limited sample size and the shorter duration of
follow-up are the limitations of the present study.
Therefore, the results of this study need to be supported
by further clinical trials performed on a larger sample of
living donors with elevated levels of UA prior to
donation procedure and with a follow-up period
longer than six months.
Conclusion
Pretransplant serum UA levels can give important clues
regarding the renal functions of the donors during the
postoperative period.
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